Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BNT3210 in Advanced Solid Tumors
NCT07886684Phase 2Not yet recruiting
- Sponsor
- BioNTech SE
- Start
- Nov 2026
- Primary completion
- Oct 2029
01
Overview
Phase 2, randomised, open-label trial of BNT3210 in solid tumor (2 arms), sponsored by BioNTech SE. Primary endpoints: Dose-Limiting Toxicities at 21 days, Treatment Emergent Adverse Events at 3 years and 2 more. Planned start Nov 2026; status: not yet recruiting.
02
Drugs
BNT3210
03
Conditions
solid tumor
Beyond the preview
Go deeper on NCT07886684.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07886684.